Document:

EXCLUSIVE
LICENSE AGREEMENT

 

Made
and effective in Jerusalem this 27 day of November 2002 (hereinafter the "Effective Date").

 

BETWEEN:

YISSUM
RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM

High
Tech Park, Edmund Safra Campus, POB 39135, Givat Ram Jerusalem 91390, Israel (hereinafter referred to as "YISSUM");

 

AND
BETWEEN:

MORRIA
BIOPHARMA CEUTICAL, INC

having
an office located at Tib street 1, Jerusalem 95450, Israel (hereinafter referred to as "the COMPANY").

 

WHEREAS,
YISSUM is the owner of certain rights, title and interest in and to the Licensed Technology (as later defined herein);

 

WHEREAS,
YISSUM is willing to grant and COMPANY desires to receive an exclusive worldwide license with rights to grant sublicenses and sub-sublicenses
under the Licensed Technology.

 

WHEREAS,
the parties have entered into a Founders Agreement concurrently herewith pursuant to which YISSUM owns a certain percentage of
shares of COMPANY.

 

NOW,
THEREFORE, for and in consideration of the premises and other good and valuable consideration, the receipt and sufficiency of which
are hereby acknowledged, YISSUM and COMPANY (hereinafter individually as a "Party"; and collectively as the "Parties")
hereto expressly agree as follows:

 

SECTION
1

 

Recitals
and Definitions

 

The
recitals hereto constitute an integral part hereof.

 

In
this Agreement, unless otherwise required or indicated by the context, the singular shall include the plural and vice-versa, and
the masculine gender shall include all other genders.

 

In
this agreement the following expressions shall have the meanings appearing alongside them, unless the context otherwise requires.

 

1.1
"Affiliates" shall mean any corporation, partnership, or other entity which at any time during the term of
this Agreement directly or through one or more intermediaries Controls or is Controlled by or is under common Control with a party
to this Agreement, but only for so long as the relationship exists. A corporation or other entity shall no longer be an Affiliate
when through loss, divestment, dilution or other reduction of ownership, the requisite Control no longer exists.

 

    	 

    	 

    

 

1.2  "Control"
or "Controls" or "Controlled" shall mean: i) in the case of a corporation, ownership or control, directly or
indirectly, of more than fifty percent (50%) of the shares of stock entitled to vote for the election of directors; or ii)
in the case of an entity other than a corporation, ownership or control, directly or indirectly, of more than fifty percent (50%)
of the assets of such entity.

 

1.3
"Field" shall mean use of lipid conjugates for the treatment of disease.

 

1.4
"Licensed Materials" shall mean materials and compounds relating to the subject matter of the Licensed
Technology, and the materials and compounds described and disclosed in the patent application.

 

1.5   "Licensed
Process" shall mean any process which is covered by any Patents in the country in which any such process is used.

 

1.6  "Licensed
Product" shall mean any product that:

 

i)  is
covered by any Patents in the country in which any such product or any pail thereof is made, used or sold; or

 

ii)  is
manufactured by using a process or is employed to practice a process which is covered by any Patents in the country in which any
such process is used or in which such product or part thereof is used or sold.

 

1.7  "Licensed
Technology" shall mean the Patents, Licensed Materials, Licensed Process, Licensed Product; and any technology, trade
secrets, intellectual property, methods, processes, know-how, show-how, data, information, inventions, improvements, or results
relating to the Patents and Licensed Materials.

 

1.8          The
term "Net Sales" shall mean the amount billed by COMPANY, Affiliates or distributors to third parties, which are not
Sublicensees, for Licensed Products, less:

 

i)discounts
allowed in amounts customary in the trade for quantity purchases, cash payments, prompt payments, wholesalers and distributors;

 

ii)sales,
tariff duties and/or use taxes directly imposed and with reference to particular sales, including VAT;

 

iii)outbound
transportation prepaid or allowed, amounts allowed or credited on returns, export licenses, import duties, value added tax, and
prepaid freight.

 

No
deductions shall be made for commissions paid to individuals whether they be with independent sales agencies or regularly employed
by COMPANY and on its payroll, or for cost of collections. Net Sales shall occur when a Licensed Product or Licensed Process shall
be invoiced. If Licensed Products or Licensed Process shall be distributed, sold or invoiced for a discounted price substantially
lower than customary in the trade or if Licensed Products shall be distributed at no cost to Affiliates, Net Sales shall be based
on the customary amount billed for such Licensed Products.

 

    	- 2 -

    	 

    

 

1.9
"Patents" shall mean, the patents and patent applications set forth on
Appendix 1, together with any and all patent applications that may in the future be filed or
granted on the intellectual property whether in the United States of America or any other country, including any and all
substitutions for and divisions, continuations, continuation-in- part, provisionals, and non-provisionals, renewals, reissues,
any foreign patent applications and divisional or national phase applications which claim priority of any application which issued
into one of the patent applications set forth in Appendix 2.

 

1.10  "Sublicensee(s)"
shall mean any third party to whom the COMPANY has granted sublicenses and sub-sublicenses pursuant to this Agreement,

 

1.11  "Sublicensing
Revenue" shall mean all cash, sublicensing or sub-sublicensing fees, and running royalties paid to COMPANY by Sublicensee(s)
in consideration for the granting of rights to the Patents and/or the Licensed Technology and in connection therewith, excluding
any payments or reimbursements for expenses directly attributable to the conduct of clinical development and/or trials by the COMPANY.

 

1.12  "First
Commercial Sale5" means in each country, the date the Licensed Product is first sold, marketed, or publicly
made available for sale. Licensed Product for use, distributed or used for clinical trial purposes shall not be considered sold,
marketed or made publicly available for sale and shall not constitute first commercial sale.

 

1.13  "Valid
Claim" shall mean (a) a claim of an issued patent which has not expired and which has not been held revoked, invalid or
unenforceable by decision of a court or other governmental agency of competent jurisdiction, unappealable or unappealed with the
time allowed for appeal having expired, and which has not been admitted to be invalid through reissue or disclaimer or otherwise;
or (b) any claim of a pending patent application, which i) was filed in good faith; and ii) has not been pending for more than
four (4) years.

 

SECTION
2

 

Grant

 

2.1  YISSUM
hereby grants to COMPANY an exclusive, worldwide right and license, with the rights to sublicense and to sub-sublicense, to the
Licensed Technology to make, have made, use, market, sell, have sold, offer to sell, import, license, and distribute, the Licensed
Technology in the Field.

 

2.2  COMPANY
shall have the right to enter into a sublicense and sub-sublicense agreements with respect to the Licensed Technology, subject
to YISSUM's prior written consent, such consent not to be unreasonably withheld. If Yissum shall not respond within fifteen (15)
business days of any written notice by the COMPANY of a proposed sub-license or sub-sublicense, including all material terms and
conditions thereof, YISSUM shall be deemed to have given consent to such sublicense or sub-sublicense, as the case may be. All
sublicenses and sub-sublicenses granted by COMPANY hereunder shall be subject to this Agreement in all respects. Each such sublicense
and sub-sublicense agreement shall include a requirement that the Sublicensee or sub-Sublicensee as the case may be, use its best
efforts to bring the subject matter of the sublicense or sub-sublicense as the case may be, into commercial use. Upon termination
of this Agreement, each Sublicensee's or sub- Sublicensee's as the case may be, rights under any sublicense or sub-sublicense agreement
shall also terminate. No sublicense or sub-sublicense shall relieve COMPANY of any of its obligations under this Agreement. COMPANY
shall forward to YISSUM a complete copy of each sublicense 01־ sub-sublicense agreement as the case may be (including, without
limitation, all amendments and addenda) granted hereunder 1within thirty (30) days after execution of such agreement
by the parties thereto. Any act or omission of the Sublicensee or sub-Sublicensee which is not promptly remedied by the COMPANY
and which would have constituted a breach of this Agreement by the COMPANY had it been an act or omission by the COMPANY, shall
constitute a breach of this Agreement.

 

    	- 3 -

    	 

    

 

SECTION
3

 

Diligence

 

3.1
COMPANY shall use its commercially reasonable best efforts to develop and commercialize Licensed Products through a commercially
reasonable program for exploitation of the Patents. In the event that COMPANY shall cease to actively engage or promote the development
and commercialization of Licensed Products for a continuous period of 30 days, YISSUM shall at its sole discretion, be entitled
to terminate this Agreement, subject to prior notice.

 

SECTION 4

 

Consideration
and Reporting

 

4.1    For
the rights, privileges and license granted hereunder, COMPANY shall pay royalties to YISSUM in the manner hereinafter provided
("Royalties") until this Agreement shall expire or be terminated. COMPANY shall pay to YISSUM:

 

a)  In
the event the COMPANY, or an Affiliate of COMPANY (in which such Affiliate shall be bound by the terms and conditions as set forth
herein), sells Licensed Product, COMPANY shall pay YISSUM a royalty of four percent (4%) of Net Sales.

 

b)  in
the event .the COMPANY receives Sublicensing Revenue for sublicensing or sub-sublicensing the Licensed Technology to a third party,
the COMPANY shall pay YISSUM a royalty of eighteen percent (18.0%) of Sublicensing Revenue received.

 

4.2    Upon
completion of the first round of equity financing by the COMPANY, the COMPANY shall reimburse YISSUM for all previous documented
expenses and costs of YISSUM relating to the filing, maintenance and prosecution of the Patents.

 

4.3    Thirty
days after the end of each calendar quarter (January 1, April 1, etc.) commencing from the date of the First Commercial Sale of
the Product or the date a sub- license is granted, whichever occurs first, the COMPANY shall furnish YISSUM with a quarterly report
(herein "Periodic Report") detailing the total sales effected during the Reporting Period and the total Royalties due
to YISSUM hi respect of that period.

 

4.4    The
Periodic Reports shall contain full particulars of all sales made by the COMPANY and/or Sub-Licensees and/or sub-Sublicensees and
all of the proceeds obtained by the COMPANY in respect of granting sublicenses and sub-Sublicenses pursuant to section 2.2 above,
including sales broken down according to countries, a breakdown of the number of Licensed Products sold, discounts, returns, the
currency in which the sales were made, invoice date and all other relevant information enabling the Royalties payable according
to section 4.1 above to be calculated. The Periodic Reports shall also specify any Net Sales to an Affiliate and shall set forth
full details thereof.

 

    	- 4 -

    	 

    

 

4.5  Within
45 days from the date prescribed for the submission of each Periodic Report, the COMPANY shall pay the Royalties and amounts due
to YISSUM in accordance with the Periodic Report.

 

4.6  The
value of each sale shall be computed on the date of sale in US Dollars based on the rates published in the Wall Street Journal.
The Royalties shall be computed and paid in US dollars. Payment of Value Added Tax (if charged) shall be added to each payment
in accordance with the statutory rate in force at such time. In event that the COMPANY is prohibited under applicable foreign currency
laws to transact in US Dollars, payment shall be made in New Israeli shekels according to the representative rate of exchange prevailing
on the date of payment. All payments required to be made in accordance with the provisions of this Agreement shall be free and
clear of any taxes or withholding of any kind. Any sum of money due to YISSUM hereunder which is not duly paid shall bear interest
from the due date of payment until the actual date of payment at the maximum rate of default interest prevaling at Bank Leumi in
respect of US dollar lines of credit.

 

4.7  The
COMPANY shall keep full and correct books of accounts in accordance with General Accepted Accounting Procedures as required by
International Accounting Standards enabling the Royalties to be calculated. The COMPANY shall procure that Sub-Licensees and sub-Sublicensees,
if any, also keep such books of accounts as aforesaid. The COMPANY shall submit to YISSUM a report authorized by a certified public
accountant containing all the particulars mentioned in section 4.3 above in respect of each Periodic Report detailing the Royalties
and Sublicensing Revenues due to it in respect of the period covered by the Periodic Report. An annual report, authorized by a
certified public accountant, shall be submitted at the end of each year, the first year for the purposes of this section commencing
on the date of the First Commercial Sale, or the date a Sub-License is granted, whichever occurs first.

 

4.8  YISSUM
and its authorized representatives may examine the COMPANY'S and Sub-Licensees' and sub-Sublicensee's
books of accounts and any report or information relating to the manufacture and marketing of the Licensed Product in order to verify
the calculation of the Royalties and Sublicensing Revenue and the accuracy of the information given to YISSUM in the aforegoing
reports. If an error greater than 5.0% in the reports of the COMPANY will be found, the COMPANY will bear the full cost of the
examination.

 

4.9       The
provisions of this section are fundamental terms of the Agreement and the breach thereof shall constitute a fundamental breach
of the Agreement.

 

SECTION 5

 

Development
and Commercialization

 

5.1        The
COMPANY undertakes, at its own expense, to use its commercially reasonable best efforts to carry out the development work necessary
to develop the Licensed Product. A breach of this provision shall be deemed to be a fundamental breach of this Agreement.

 

5.2  The
COMPANY shall give YISSUM written notice of the First Commercial Sale of the Product within 30 days thereof. This provision is
a fundamental term of the Agreement.

 

    	- 5 -

    	 

    

 

SECTION
6

 

Ownership

 

6.        All
rights in the Know-How, the Research, and the Research Results shall be solely owned by Yissum, and the Company shall hold the
rights granted pursuant to the License as trustee for Yissum and make use of them solely in accordance with the terms of this Agreement.

 

Patents

 

7.1     COMPANY
shall assume full responsibility and conduct of patent prosecution and maintenance of the Patents and will be responsible for preparing,
filing, prosecuting and maintaining all patents and shall use patent counsel of its own choice, subject to the approval of YISSUM
(not to be unreasonably withheld), at COMPANY'S own expense. COMPANY agrees to pay all costs,
incident to the United States and foreign applications, patents and like protection, including all costs incurred for filing, prosecution,
issuance and maintenance fees as well as any costs incurred in filing continuations, continuations-in-part, divisional or related
applications and any re-examination or reissue proceedings. COMPANY shall file and maintain patent applications corresponding to
the Licensed Technology in such countries as COMPANY in its sole discretion shall select but shall notify and consult with YISSUM
as to those countries where it shall not file and maintain patent applications.

 

7.2     COMPANY
agrees to keep YISSUM informed, of filing and prosecutions pursuant to this Section 7 including submitting to YISSUM copies of
all official actions, applications, continuations, re־xaminations, re-issues, divisionals or like proceedings and responses
thereto. COMPANY shall consult with YISSUM regarding any abandonment of the prosecution of patents application within the Patents.

 

7.3  Each
and every patent application as aforesaid shall be registered exclusively in the name of YISSUM at the COMPANY'S
sole expense.

 

7.4  In
the event that COMPANY decides not to continue prosecution of a patent application to issuance or maintain any patent application
or patent on technology within the Patents in a certain jurisdiction, COMPANY shall timely notify YISSUM in writing in order that
YISSUM may continue said prosecution or maintenance of such patent applications at its option and at its own expense in such jurisdiction.
In the event that the COMPANY shall elect not to file or prosecute or discontinue or abandon the filing, prosecution or maintenance
of Patents in certain countries and YISSUM shall do so at its expense, then the License shall no longer be applicable in such countries.
If COMPANY fails to notify YISSUM in sufficient time for YISSUM to assume the cost, COMPANY shall be considered in default of this
Agreement.

 

7.5     COMPANY
and all its Sublicensees and sub-Sublicensees shall mark all products covered by Patents with patent numbers in accordance with
the statutory requirements in the country(ies) of manufacture, use, and sale, and pending the issue of any patents.

 

7.6     The
COMPANY undertakes to act forthwith at its own expense to provide full protection against a third party's infringement of the Patents
and/or the patents and/or any other right therein and forthwith to advise YISSUM upon learning of the infringement. The COMPANY
shall give YISSUM immediate notice of any approach made to it by a patent examiner and/or attorney in connection with the subject
matter of this Agreement. The COMPANY shall only reply to such approaches after consultation with YISSUM and subject to its consent.

 

    	- 6 -

    	 

    

 

7.7     The
COMPANY shall use its best efforts at its own expense to defend any action, claim or demand made by any entity in connection with
rights in the Patent and/or patents and shall give notice to YISSUM immediately upon learning of any such action, claim or
demand as aforesaid.

 

7.8     Any
settlement, consent judgment or other voluntary final disposition of any action pursuant to section 7.7 above shall not be entered
into without the prior written consent of YISSUM.

 

7.9     Subject
to reimbursement of documented reasonable out-of- pocket expenses incurred by the COMPANY in relation to any legal action contemplated
under the provisions of section 7.7 above, any award in favor of YISSUM and/or the COMPANY resulting from such legal action shall
be divided equally between the COMPANY and YISSUM. Any recovery of damages by COMPANY for each such suit shall be applied first
in satisfaction of any unreimbursed documented reasonable expenses and legal fees of COMPANY relating to such suit.

 

7.10   The
obligation of the COMPANY to notify YISSUM as stated in this section 7 are fundamental terms of this Agreement. A breach thereof
shall constitute a fundamental breach of the Agreement, and YISSUM, at its sole discretion, shall have the right to terminate the
Agreement immediately under terms and conditions as stated in section 11,

 

SECTION
7

 

Confidentiality

 

8.1       The
COMPANY warrants and undertakes that during the term of this Agreement and subsequent thereto, it shall maintain full and absolute
confidentiality and shall also be liable for its employees and/or representatives and/or persons acting on its behalf maintaining
absolute confidentiality concerning inter alia any and all information, details and data which is in and/or comes to its knowledge
and/or that of its employees, representatives and/or any person acting on its behalf directly or indirectly relating to the Licensed
Technology. The COMPANY undertakes not to convey or disclose anything in connection with the aforegoing to any entity.

 

8.2       The
obligation contained in this section shall not apply to information which is in the public domain as at the date hereof or to information
which hereafter comes into the public domain, unless the COMPANY breaches its obligations pursuant to this Agreement as a result
thereof the information comes into the public domain.

 

    	- 7 -

    	 

    

 

8.3       Notwithstanding
Section 8.1, the COMPANY may disclose details and information to its employees and Sublicensees, as necessary for the performance
of its obligations pursuant to this Agreement, provided that it procures that its employees and Sublicensees execute a confidentiality
agreement, in the form attached hereto as Appendix 4.

 

8.4       Without
prejudice to the aforegoing, the COMPANY shall not mention the Hebrew University's and/or YISSUM's name, unless required by law,
in any manner or for any purpose in connection with this Agreement, the subject of the research or any matter relating to the Licensed
Technology without obtaining YISSUM's prior written consent.

 

8.5       YISSUM
shall procure that its researchers, employees and/or any other person connected with it with regard to the Licensed Technology
execute the confidentiality agreement in the form annexed hereto as Append 3.

 

8.6       As
a precondition to any sub-license, the COMPANY shall ensure that the Sublicensee procures that the employees and persons engaged
thereby execute a confidentiality agreement in the form annexed hereto as Appendix 3.

 

8.7       The
breach of this section, by any person or entity other than YISSUM or the COMPANY shall not be deemed a breach of the Agreement,
if YISSUM or the COMPANY prove that they took all reasonable steps to avoid the breach.

 

8.8       The
end or termination of this Agreement shall not release the parties from their obligations pursuant to this section.

 

8.9       The
provisions of this section are fundamental provisions of the Agreement. Their breach shall constitute a fundamental breach of the
Agreement, and YISSUM, at its sole discretion, shall have the right to terminate the Agreement immediately.

 

SECTION
8

 

Publications

 

9.1       YISSUM
shall ensure that no publications in writing, in scientific journals or orally at scientific conventions relating to the Licensed
Technology, which are subject to the terms and conditions of this Agreement, are published by it or its researchers.

 

9.2       Dr.
Saul Yedgar agrees not to disclose or divulge to any other person, party, or entity the confidential information or any information
and material of the COMPANY, unless authorized by COMPANY, which authorization shall not be unreasonably withheld.

 

SECTION 9

 

Liability
and Indemnity

 

10.1  YISSUM expressly disclaims any and all implied or express warranties and makes no express or implied warranties of merchantability
or fitness for any particular purpose of the Licensed Technology.

 

    	- 8 -

    	 

    

 

10.2    The
COMPANY shall be liable for any loss, injury and/or damage whatsoever caused to its employees and/or any person acting on its behalf
and/or to the employees of YISSUM and/or any person acting on its behalf and/or to any third party by reason of the COMPANY's acts
and/or omissions pursuant to this Agreement and/or by reason of any use made of the Licensed Technology by the COMPANY and/or any
third party whatsoever.

 

10.3    The
COMPANY undertakes to compensate, indemnify, defend and hold harmless YISSUM and/or any person acting on its behalf and/or any
of its employees and/or representatives and/or the University (herein referred to as "Indemnitees") against any liability
including product liability, damage, loss or expenses including reasonable legal fees and litigation expenses incurred by or imposed
upon the Indemnitees by reason of its acts and/or omissions and/or which derive from its use, development, manufacture, marketing,
sale and/or sub-licensing and/or sub-sublicensing of the Licensed Product, or Licensed Technology.

 

10.4    The
COMPANY shall obtain prior to the commencement of clinical trials by the COMPANY and/or on behalf or at the request of the COMPANY
and prior to the First Commercial Sale, comprehensive general liability insurance which shall provide:

 

		(i)	Product liability coverage,

 

		(ii)	Contractual liability coverage for the COMPANY's indemnification under this Agreement and in particular as stated in section
10.3 and

 

		(iii)	Name YISSUM as an additional insured.

 

All
required insurance will be at the COMPANY's sole cost and expense.

 

10.5    The
COMPANY shall provide YISSUM with written evidence of such insurance upon request of YISSUM. The COMPANY shall provide YISSUM with
written notice at least fifteen days prior to the cancellation, non-renewal or material change in such insurance; if the COMPANY
does not obtain replacement insurance providing comparable coverage within such fifteen day period, YISSUM shall have the right
to terminate this Agreement effective at the end of such fifteen day period without notice or any additional waiting periods.

 

10.6
The COMPANY shall maintain comprehensive general liability insurance beyond the expiration or termination of this Agreement during
the period that a Licensed Product relating to and/or developed pursuant to this Agreement is being commercially distributed or
sold by the COMPANY and/or Sub-Licensee.

 

10.7
YISSUM represents and warrants that to the best of its actual knowledge: (i) it has the full power to enter into this Agreement,
to carry out its obligations under this Agreement, and to grant the rights granted to COMPANY herein; (ii) it has not previously
granted and shall not grant to any third party any rights which are inconsistent with the rights granted to COMPANY herein; (iii)
it has the rights, title, and interest in and to the Patents, as et out in Appendix 2; and (iv) no consent, approval or authorization
of any other party is required.

 

    	- 9 -

    	 

    

 

10.8
COMPANY represents that: i) it has full coiporate power and authority to enter into this Agreement and carry out all the provisions
of this Agreement; ii) it is authorized to execute this Agreement 011 its behalf; iii) the person executing this Agreement is duly
authorized to do so; and iv) no consent, approval or authorization of any other party is required.

 

SECTION 10

 

Termination
of the Agreement

 

11.1  Unless
earlier terminated, as hereinafter provided, the term of this Agreement shall be for the longer of twenty (20) years or the term
of any patent or patent application having a Valid Claim covering the Patents.

 

11.2  In
the event of default or failure by COMPANY to perform any of the terms, covenants or provisions of this Agreement, COMPANY shall
have thirty (30) days after the giving of written notice of such default by YISSUM to correct such default, but in the event that
such default or breach cannot be rectified, YISSUM may terminate this Agreement with immediate effect. If a default capable of
being rectified is not corrected within the said thirty (30) day period, YISSUM shall have the right, at its option, to cancel
and terminate this Agreement at any time thereafter.

 

11.3         YISSUM
shall have the right, at its option, to cancel and terminate this Agreement in the event that COMPANY shall become involved in
insolvency, bankruptcy, liquidation, winding-up or receivership proceedings or in the event that an attachment is placed on assets
of the COMPANY affecting the operation of its business. The COMPANY shall immediately notify YISSUM upon commencement of any bankruptcy,
insolvency, liquidation, winding-up or receivership proceedings or the placing of an attachment on its assets.

 

11.4         In
the event of termination of this Agreement for any reason whatsoever, the license shall terminate and all rights to the Patents
and Licensed Technology shall revert to YISSUM and the COMPANY may make no further use thereof. Notwithstanding the aforesaid,
the end or termination of this Agreement shall not release the COMPANY from its obligation to carry out any financial or other
obligation which it was liable to perform prior to the Agreement's end or termination.

 

11.5         Upon
termination of this Agreement for any reason, nothing herein shall be construed to release either party from any obligation that
matured prior to the effective date of such termination; and Sections 1 and 8-15 shall survive any such termination.

 

11.6         No
termination of this Agreement shall constitute a termination or a waiver of any rights of either Party against the other Party
accruing at or prior to the time of such termination.

 

11.7         COMPANY
shall have the right to terminate this Agreement at any time on three (3) months notice to YISSUM, and upon payment of all amounts
due YISSUM through the effective date of the termination.

 

    	- 10 -

    	 

    

 

SECTION
11

 

Law

 

12.1  The
provisions of this Agreement and anything else concerning the relationship between the parties in connection with the subject matter
of this Agreement shall be governed by Israeli law. The parties hereby submit to the exclusive jurisdiction of the appropriate
courts in Jerusalem.

 

12.2         Notwithstanding
the above, the COMPANY hereby agrees that, in the event that no treaty exists upholding the enforceability of temporary orders
issued by Israeli courts in the foreign jurisdiction in which YISSUM may require such an order to be upheld, YISSUM may, at its
own discretion, elect the place of jurisdiction for the obtaining of writs against the COMPANY.

 

12.3
The COMPANY undertakes not to object to the enforcement against it of writs issued by any aforesaid jurisdiction under such circumstances.

 

SECTION
12

 

Arbitration

 

13.1   All
differences and disputes arising between the parties in connection with the Agreement and/or its interpretation and/or its performance
and/or breach, shall be referred for the decision of a single arbitrator, who shall be appointed by agreement between the parties.

 

13.2   Should
the parties not reach agreement as to the arbitrator's identity, the arbitrator shall be appointed by the Chairman of the Israeli
Bar Association on the application of either of the parties.

 

13.3      The
arbitration shall be held in Israel. The arbitrator shall not be bound by the civil procedure regulations and laws of evidence
but shall be bound by the substantive law of Israel and be liable to give grounds for his decision.

 

13.4
The arbitrator's decision shall be final and shall bind the parties.

 

13.5
The execution of this Agreement shall constitute the execution of an arbitration deed.

 

SECTION
13

 

Miscellaneous

 

14.1    This
Agreement shall be binding upon and shall inure to the benefit of YISSUM and its assigns and successors in interest, and shall
be binding upon and shall inure to the benefit of COMPANY and its assigns and successors to all or substantially all of its assets
or business to which this Agreement relates, but shall not otherwise be assignable or assigned by COMPANY without prior written
approval by YISSUM being first obtained, which approval shall not be unreasonably withheld.

 

    	- 11 -

    	 

    

 

14.2  If
any provision of this Agreement shall be declared by a court of competent jurisdiction to be invalid, illegal or incapable of being
enforced in whole or in part, the remaining conditions and provisions or portions thereof shall nevertheless remain in full force
and effect and enforceable to the extent they are valid, legal and enforceable, and no provision shall be deemed dependent upon
any other covenant or provision unless so expressed herein.

 

14.3         All
Parties hereby agree that neither Party intends to violate any public policy, statutory or common law, rule, regulation, treaty
or decision of any government agency or executive body thereof of any country or community or association of countries; that if
any word, sentence, paragraph or clause or combination thereof of this Agreement is found, by a court or executive body with judicial
powers having jurisdiction over this Agreement or any of its Parties hereto, in a final unappealed order to be in violation of
any such provision in any country or community or association of countries, such words, sentences, paragraphs or clauses or combination
shall be inoperative in such country or community or association of countries, and the remainder of this Agreement shall remain
binding upon the Parties hereto.

 

14.4         
The Parties covenant and agree that if a Party fails or neglects for any reason to take advantage of any of the terms provided
for the termination of this Agreement or if a Party, having the right to declare this Agreement terminated, shall fail to do so,
any such failure or neglect by such Party shall not be a waiver or be deemed or be construed to be a waiver of any cause for the
termination of this Agreement subsequently arising, or as a waiver of any of the terms, covenants or conditions of this Agreement
or of the performance thereof. None of the terms, covenants and conditions of this Agreement may be waived by a Party except by
its written consent.

 

14.5         This
Agreement contains the entire agreement and understanding of the parties with respect to the subject matter hereof, supersedes
any prior agreements and understandings with respect thereto and cannot be modified, amended or waived, in whole or in part, except
in writing signed by the party to be charged. Any such purported modification, amendment, or waiver shall be null and void. A discharge
of the terms of this Agreement shall not be deemed valid unless by full performance of the parties hereto or by writing signed
by the parties hereto. A waiver by YISSUM of any breach by COMPANY of any provision or condition of this Agreement to be performed
by COMPANY shall not be deemed a waiver of similar or dissimilar provisions or conditions at the same or any prior or subsequent
time.

 

14.6         Each
party shall bear its own legal expenses involved in the making of this Agreement.

 

14.7         The
headings to the sections in this agreement are for the sake of convenience only and shall not serve in the Agreement's interpretation.

 

14.8
The COMPANY shall disclose to YISSUM any existing agreement and/or arrangement or relationship of any land between it and employees
of YISSUM and/or the Hebrew University of Jerusalem with respect to the Licensed Technology and in connection therewith and shall
not enter into any agreement or arrangement with any employees of YISSUM and/or the Hebrew University of Jerusalem, as aforesaid,
without the prior written consent of YISSUM.

 

    	- 12 -

    	 

    

 

14.9
The appendixes annexed hereto constitute an integral pail hereof and shall be read jointly with its terms and provisions.

 

SECTION
14

 

Notices

 

15.1
All notices and communications pursuant to this Agreement shall be made in writing and sent by registered mail to or served at
the following addresses:

 

YISSUM
RESEARCH DEVELOPMENT COMPANY

High
Tech Park, Edmund Safra Campus,

POB
39135, Givat Ram Jerusalem 91390, Israel

 

MORRIA
BIOPH ARM A CEUTIC AL,

INC. 1 Taib St., Jerusalem 95405, Israel

 

with
a copy to Mark Cohen, Adv.

Eitan,
Pearl, Latzer & Cohen-Zedek

Gav
Yam 2, Shenkar street 7

Herzelia
Pituach, Israel

 

or
such other address furnished in writing by one party to the other. Any notice sent as aforesaid shall be deemed to have been received
seven days after being posted by registered mail

 

IN
WITNESS WHEREOF, the Parties hereto have executed and delivered this Agreement in multiple originals by their duly authorized officers
and representatives on the respective dates shown below, but effective as of the Effective Date. The undersigned representative
of YISSUM is authorized to execute this Agreement on its behalf and bind YISSUM to the terms and conditions set forth.

 

    	- 13 -

    	 

    

 

	YISSUM RESEARCH	 	 	 
	DEVELOPMENT COMPANY	 	MORRIA BIOPHARMACEUTICAL INC.
	 	 	 	 	 
	By:	/s/ AVI BARAK	 	By:	/s / SAUL YEDGAR
	 	 	 	 	 
	Name:	 	 	Name:	 
	 	 	 	 	 
	Title:	 	 	Title:	 
	 	 	 	 	 
	Date: 	November 26 2002 	 	Date:	Nov  27 2002
	 	 	 	 	 
	By:	/s/ REUVEN RON	 	By:	/s/ YUVAL COEHN
	 	 	 	 	 
	Name:	 	 	Name:	 
	 	 	 	 	 
	Title:	VP MARKETING LIFE SCIENCE  &MEDICINE	 	Title:	PRESIDENT
	 	 	 	 	 
	Date:	November 26 2002	 	Date:	Nov  27 2002

 

1,
Saul Yedgar, acknowledge that I have read this Agreement in its entirety ׳and that I shall use reasonable efforts to uphold
my individual obligations and responsibilities as set forth herein:

 

	By:	/s/ SAUL YEDGAR	 	Date: Nov  27 2002
	 	Signature	 	 

 

    	- 14 -

    	 

    

 

APPENDIX 1

 

	Patent No./ Patent
 Application	Issue
 Date/Filing
 Date	Named
 Inventors	Title	Serial Number
	EPLC P-2507-AU Yissum No. 2510	10־Jan-01	Saul Yedgar	Use of lipid conjugates in the treatment of disease	 
	EPLC P-2507-CA Yissum No. 2510	10-Jan-01	Saul Yedgar	Use of lipid conjugates in the treatment of disease	 
	EPLC P-2507-EP Yissum No. 2510	10-Jan01־	Saul Yedgar	Use of lipid conjugates in the treatment of disease	01900237.7
	EPLC P-2507-IL Yissum No. 2510	10-Jan-01	Saul Yedgar	Use of lipid conjugates in the treatment of disease	150628
	EPLC P-2507-JP Yissum No. 2510	10־Jan-01	Saul Yedgar	Use of lipid conjugates in the treatment of disease	2001-551427
	EPLC P-2507-PC Yissum No. 2510	10־Jan-01	Saul Yedgar׳	Use of lipid conjugates in the treatment of disease	PCT/IL01/00023
	EPLC P-2507-US Yissum No. 2510	10-Jan-01	Saul Yedgar	Use of lipid conjugates in the treatment of disease	09/756,765
	EPLC P-2507-US1 Yissum No. 2510	 	Saul Yedgar	Use of lipid conjugates in the treatment of disease	 
	EPLC P-2507-USP Yissum No. 2510	10־Jan00־	Saul Yedgar	Use of lipid conjugates in the treatment of disease	60/174,907
	EPLC P-2507-USP1 Yissum No. 2510	10-Jan-00	Saul Yedgar	Use of lipid conjugates in the treatment of disease	60/174,905

 

    	- 15 -

    	 

    

 

APPENDIX 2

 

I,
the undersigned ___________________, do hereby declare that I have knowledge of research on the subject _ ____________and that it is
funded by ______________________.

 

		1.	I do hereby undertake to keep secret and to do all in my power to prevent unauthorized disclosure
of all information brought to my knowledge regarding the above research. I do further hereby consent to refrain from making public
any work, report of work, or any other information concerning the above project, or to present in any other manner any work, report
or information in writing and/or orally, without prior permission from YISSUM and___________________  This undertaking does not include information
already disclosed in publication generally in the public domain, and under the contract dated between YISSUM and ______________________.

 

		2.	It is hereby agreed that the undertaking of section I above does not apply to these dissertations
presented by candidates for Masters and Doctoral Degrees, to internal referee committees of the University, who will themselves
ensure that such information is not received by unauthorized bodies.

 

		3.	In addition to all the above, I do also undertake to fully observe the instructions of the University
administrative authorities as published by The Hebrew University of Jerusalem (Order No. 15-001 and 15-011).

 

		4.	I
do hereby undertake to keep all the above secret, and not to transfer to any person or persons, at any time, any information,
in any way connected with the above subject without receiving the written permission of both YISSUM and_________________________________

 

	 	 	 
	Signature	 	Date
	 	 	 
	 	 	 
	Form No.	 	 
	 	 	 
	 	 	 
	Israel I.D. Card/Passport Number	 	 

 

CONFIDENTIAL

 

    	- 16 -

    	 

    

 

		
        Morria Biopharmaceuticals Plc

        (Company no. 5252842)

        Registered in England

         

        London Office

        53 Davies street

        Mayfair

        London W1K 5JH

        Tel: +44 (0)207 152 6341

        Fax: +44 (0) 207 152 6342

        Email: info@morria.com

         

        Registered Office Address

        Thames House

        Portsmouth Road

        Esher

        Surrey

        KT10 9AD

 

March, 4, 2012

Via E-Mail

Mr. Trachtenberg

YISSUM Research and Development Company of the

Hebrew University of Jerusalem

P.O. Box 39135 Jerusalem 91390

 

	 	RE:	Updated Appendix 1 of the Exclusive License Agreement between Morria Biopharmaceuticals Inc. and Yissum

 

Dear Mr. Trachtenberg,

 

According to section 7.2 to the Exclusive License Agreement
between Yissum Research and Development Company of the Hebrew University of Jerusalem (“Yissum”), and Morria
Biopharmaceuticals (“Morria”) executed on November 27, 2002 (the “Agreement”), please find
attached an updated Appendix 1, which is herby incorporated into the Agreement.

 

Furthermore, please update your records, as to the notice address
of Morria, as defined in section 15.1 of the Agreement to:

 

Morria Biopharmaceuticals Plc

Thames House

Portsmouth Road

Esher

Surrey

KT10 9AD

 

With a copy to:

Mark S. Cohen

Pearl Cohen Zedek Latzer, LLP

1500 Broadway, 12th Floor

New York, NY 10036

 

We will continue to update Yissum with all future patent filing
by Morria, according to the Agreement.

 

Please sign and return the letter, acknowledging receipt of
this Update letter.

 

	 	Yours sincerely,
	 	 
	 	Daniel Intract

cc: Mark Cohen, Executive Chairman

 

The undersigned confirms receipt of the Update Letter.

 

	 
	YISSUM

Research and Development Company of the Hebrew University of
Jerusalem

	By:  	 

Date: March ___, 2012

 

    	- 17 -

    	 

    

 

Appendix 1

 

Morria Patent Schedule

 

US Granted Patents

 

	PCZL Ref.

    No.	 	Application #

    / Patent No.	 	Assignee	 	Filing Date	 	Priority Date	 	Status	 	Inventor/s	 	Claimed
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	P-2507-US	 	09/756,765

        Patent No. 7,034,006
	 	YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM	 	10-Jan-2001	 	10-Jan-2000	 	Patented	 	YEDGAR, Saul; SHOSEYOV, David; GOLOMB, Gershon; REICH, Reuven; GINSBURG, Isaac; HIGAZI, Abd-al-Roof;
    LIGUMSKI, Moshe; KRIMSKY, Miron; OJCIUS, David; YARD, Benito Antonio; van der WOUDE, Fokko Johannes; SCHNITZER, Edit	 	Phosphatidylethanolamine glycosaminoglycan conjugates, including HyPE.
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	P-2507-US1	 	10/627,981

        Patent No. 7,101,859
	 	YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM	 	28-July-2003	 	10-Jan-2000	 	Patented	 	YEDGAR, Saul; KRIMSKY, Miron; BECK, Grietje; YARD, Benito Antonio; van der WOUDE, Fokko Johannes	 	Methods of treating sepsis with MFAIDs, including with HyPE.

 

    	- 18 -

    	 

    

 

	PCZL Ref.

    No.	 	Application #

    / Patent No.	 	Assignee	 	Filing Date	 	Priority Date	 	Status	 	Inventor/s	 	Claimed
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	P-2507-US2	 	10/790,182

        Patent No. 7,141,552
	 	YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM	 	02-Mar-2004	 	10-Jan-2000	 	Patented	 	YEDGAR, Saul; LIGUMSKI, Moshe; KRIMSKY, Miron	 	Methods of treating intestinal diseases with MFAIDs.
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	P-2507-US4	 	10/989,606;

        Patent No. 7,811,999
	 	YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM	 	17-Nov-2004	 	10-Jan-2000	 	Patented	 	YEDGAR, Saul; SHOSEYOV, David	 	Methods of treating obstructive respiratory diseases with glycosaminoglycan conjugates with
    phosphatidylethanolamine or phosphatidylserine.
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	P-2507-US5	 	10/952,496

        Patent No. 7,393,938
	 	YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM	 	29-Sep-2004	 	10-Jan-2000	 	Patented	 	YEDGAR, Saul	 	Phosphatidylserine glycosaminoglycan conjugates.

 

    	- 19 -

    	 

    

 

	PCZL Ref.

    No.	 	Application #

    / Patent No.	 	Assignee	 	Filing Date	 	Priority Date	 	Status	 	Inventor/s	 	Claimed
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	P-2507-US6	 	10/989,607

        Patent No. 7,772,196
	 	YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM	 	17-Nov-2004	 	10-Jan-2000	 	Patented	 	YEDGAR, Saul	 	Methods of treating a dermatological condition with phosphatidylethanolamine glycosaminoglycan
    conjugates, including HyPE.
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	P-2507-US7	 	11/220,965

        Patent No. 7,504,384
	 	YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM	 	08-Sep-2005	 	10-Jan-2000	 	Patented	 	YEDGAR, Saul; OJCIUS, David	 	Methods of treating infections with phosphatidylethanolamine glycosaminoglycan conjugates,
    including HyPE.
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	P-2507-US9	 	11/285,375

        Patent No.

        8,076,312
	 	YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM	 	23-Nov-2005	 	10-Jan-2000	 	Patented	 	YEDGAR, Saul	 	Methods of treating asthma, COPD and allergic rhinitis with phosphatidylethanolamine glycosaminoglycan
    conjugates, including HyPE.

 

    	- 20 -

    	 

    

 

	PCZL Ref.

    No.	 	Application #

    / Patent No.	 	Assignee	 	Filing Date	 	Priority Date	 	Status	 	Inventor/s	 	Claimed
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	P-2507-US16	 	11/475,240

        Patent No. 7,608,598
	 	YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM	 	27-June-2006	 	10-Jan-2000	 	Patented	 	YEDGAR, Saul	 	Methods of treating conjuctivitis with phosphatidylethanolamine glycosaminoglycan conjugates,
    including HyPE.
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	P-2507-US19	 	12/010,315

        Patent No.

        7,893,226

         
	 	YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM	 	23-Jan-2008	 	10-Jan-2000	 	Patented	 	YEDGAR, Saul	 	Methods of manufacturing MFAIDs.

 

    	- 21 -

    	 

    

 

US Pending Patent Applications

 

	PCZL Ref.

    No.	 	Application #	 	Filing Date	 	Priority Date	 	Status	 	Inventor/s	 	Claimed
	 	 	 	 	 	 	 	 	 	 	 	 	 
	P-2507-US3	 	10/919,523	 	17-Aug-2004	 	10-Jan-2000	 	Pending	 	YEDGAR, Saul	 	Methods of treating nervous system disorders with phosphatidylethanolamine glycosaminoglycan
    conjugates
	 	 	 	 	 	 	 	 	 	 	 	 	 
	P-2507-US8	 	11/524,519	 	21-Sep-2006	 	10-Jan-2000	 	Pending	 	YEDGAR, Saul; KRIMSKY, Miron; INGBER, Arie	 	Methods of treating a dermatological condition with MFAIDs.
	 	 	 	 	 	 	 	 	 	 	 	 	 
	P-2507-US17	 	11/598,812	 	14-Nov-2006	 	10-Jan-2000	 	Pending	 	YEDGAR, Saul; LIGUMSKI, Moshe; KRIMSKY, Miron	 	Methods of treating Crohn’s disease and ulcerative colitis with MFAIDs, including HyPE.
	 	 	 	 	 	 	 	 	 	 	 	 	 
	P-2507-US15	 	11/822,423	 	05-July-2007	 	10-Jan-2000	 	Pending	 	YEDGAR, Saul	 	Methods of treating neoplasias or cancers with MFAIDs.
	 	 	 	 	 	 	 	 	 	 	 	 	 
	P-2507-US20	 	12/406,130	 	18-Mar-2009	 	10-Jan-2001	 	Pending	 	YEDGAR, Saul	 	Methods of inhibiting angiogenisis or diseases associated with angiogenesis using  MFAIDs
	 	 	 	 	 	 	 	 	 	 	 	 	 
	P-2507-US22	 	12/605,887	 	26-Oct-2009	 	10-Jan-2000	 	Pending	 	YEDGAR, Saul	 	Methods of treating conjuctivitis with MFAIDs.
	 	 	 	 	 	 	 	 	 	 	 	 	 
	P-2507-US23	 	12/820,161	 	22-June-2010	 	10-Jan-2000	 	Pending	 	YEDGAR, Saul	 	Methods of treating a dermatological condition with phosphatidylserine glycosaminoglycan
    conjugates.
	 	 	 	 	 	 	 	 	 	 	 	 	 
	P-2507-US24	 	13/031,990	 	22-Feb-2011	 	10-Jan-2000	 	Pending	 	YEDGAR, Saul	 	MFAID compounds.
	 	 	 	 	 	 	 	 	 	 	 	 	 
	P-8131-US	 	11/496,728	 	01-Aug-2006	 	03-Aug-2005	 	Pending	 	YEDGAR, Saul; PRINCE, Alice	 	Methods of treating cystic fibrosis with MFAIDs.

 

    	- 22 -

    	 

    

 

	PCZL Ref.

    No.	 	Application #	 	Filing Date	 	Priority Date	 	Status	 	Inventor/s	 	Claimed
	 	 	 	 	 	 	 	 	 	 	 	 	 
	P-8653-US	 	11/716,015	 	09-Mar-2007	 	09-Mar-2006	 	Pending	 	YEDGAR, Saul	 	Catheters and stents coated with MFAIDs.
	 	 	 	 	 	 	 	 	 	 	 	 	 
	P-8967-US	 	11/984,224	 	14-Nov-2007	 	14-Nov-2006	 	Pending	 	YEDGAR, Saul; COHEN, Yuval	 	A contact lens comprising a phosphatidylethanolamine glycosaminoglycan conjugate.
	 	 	 	 	 	 	 	 	 	 	 	 	 
	P-8967-US1	 	11/984,223	 	14-Nov-2007	 	14-Nov-2006	 	Pending	 	YEDGAR, Saul; COHEN, Yuval	 	Methods of treating eye diseases and disorders with MFAIDs.
	 	 	 	 	 	 	 	 	 	 	 	 	 
	P-71126-US	 	12/997,014	 	09-Dec-2010	 	11-May-2009	 	Pending	 	YEDGAR, Saul; COHEN, Yuval; BONDI, Joseph V.	 	Low molecular weight phospholipid-glycosaminoglycan conjugate compositions.
	 	 	 	 	 	 	 	 	 	 	 	 	 
	P-73006-US	 	12/463,792	 	11-May-2009	 	29-Sep-2004	 	Pending	 	YEDGAR, Saul	 	Methods of treating cancers and disorders associated with matrix metalloproteinases using
    MFAIDs.
	 	 	 	 	 	 	 	 	 	 	 	 	 
	P-75622-US	 	13/283,020	 	27-Oct-2011	 	17-Nov-2005	 	Pending	 	YEDGAR, Saul	 	Methods of treating chronic rhinosinusitis or nasal polyps with MFAIDs.
	 	 	 	 	 	 	 	 	 	 	 	 	 
	P-75630-US	 	13/316,592	 	12-Dec-2011	 	17-Nov-2005	 	Pending	 	YEDGAR, Saul	 	Methods of treating allergic rhinitis with MFAIDs.
	 	 	 	 	 	 	 	 	 	 	 	 	 
	P-74830-USP	 	61/485,192	 	12-May-2011	 	12-May-2001	 	Pending	 	YEDGAR, Saul	 	Liposomes comprising a lipid bilayer and a polymer conjugated lipid and methods of treating
    diseases (including obstructive pulmonary diseases and cystic fibrosis) using the liposomes.

 

    	- 23 -

    	 

    

 

Rest of the World Granted Patents

 

	PCZL Ref.

    No.	 	Country	 	Application # /

    Patent No	 	Filing Date	 	Priority

    Date	 	Status	 	Inventor/s	 	Claimed
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	P-2507-AU	 	Australia	 	23935/01

        Patent No. 785017
	 	10-Jan-2001	 	10-Jan-2000	 	Patented	 	YEDGAR, Saul; SHOSEYOV, David; GOLOMB, Gershon; REICH, Reuven; GINSBURG, Isaac; HIGAZI, Abd-al-Roof;
    LIGUMSKI, Moshe; KRIMSKY, Miron; OJCIUS, David; YARD, Benito Antonio; van der WOUDE, Fokko Johannes; SCHNITZER, Edit	 	1. Glycosaminoglycan MFAIDs.

        2. Use of Glycosaminoglycan
        MFAIDs to treat asthma, COPD and dermatologic conditions.

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	P-2507-CA	 	Canada	 	2,397,016	 	10-Jan-2001	 	10-Jan-2000	 	Patented	 	YEDGAR, Saul; SHOSEYOV, David; GOLOMB, Gershon; REICH, Reuven; GINSBURG, Isaac; HIGAZI, Abd-al-Roof;
    LIGUMSKI, Moshe; KRIMSKY, Miron; OJCIUS, David; YARD, Benito Antonio; van der WOUDE, Fokko Johannes; SCHNITZER, Edit	 	1. Phosphotidylethanolamine
        glycosaminoglycan conjugates.

        2. Use of Glycosaminoglycan
        MFAIDs to treat asthma, COPD and dermatologic conditions.

 

    	- 24 -

    	 

    

 

	PCZL Ref.

    No.	 	Country	 	Application # /

    Patent No	 	Filing Date	 	Priority

    Date	 	Status	 	Inventor/s	 	Claimed
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	P-2507-IL	 	Israel	 	150628	 	10-Jan-2001	 	10-Jan-2000	 	Patented	 	YEDGAR, Saul; SHOSEYOV, David; GOLOMB, Gershon; REICH, Reuven; GINSBURG, Isaac; HIGAZI, Abd-al-Roof;
    LIGUMSKI, Moshe; KRIMSKY, Miron; OJCIUS, David; YARD, Benito Antonio; van der WOUDE, Fokko Johannes; SCHNITZER, Edit	 	Phosphotidylethanolamine glycosaminoglycan conjugates.
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	P-2507-JP	 	Japan	 	2001-551427

        4,782,966
	 	10-Jan-2001	 	10-Jan-2000	 	Patented	 	YEDGAR, Saul; SHOSEYOV, David; GOLOMB, Gershon; REICH, Reuven; GINSBURG, Isaac; HIGAZI, Abd-al-Roof;
    LIGUMSKI, Moshe; KRIMSKY, Miron; OJCIUS, David; YARD, Benito Antonio; van der WOUDE, Fokko Johannes; SCHNITZER, Edit	 	1. Phosphotidylethanolamine
        glycosaminoglycan conjugates.

        2. Use of phosphotidylethanolamine
        glycosaminoglycan conjugates to treat asthma, obstructive respiratory diseases, dermatologic conditions or intestinal
        diseases.

 

    	- 25 -

    	 

    

 

	PCZL Ref.

    No.	 	Country	 	Application # /

    Patent No	 	Filing Date	 	Priority

    Date	 	Status	 	Inventor/s	 	Claimed
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	P-2507-AU2	 	Australia	 	2005218545	 	02-Mar-2005	 	2-Mar-2004	 	Patented	 	YEDGAR, Saul	 	1. MFAID compounds.

        2. Use of MFAID compounds
        to treat sepsis, an intestinal disease, a CNS disease or disorder, an obstructive respiratory disease or a dermatologic
        condition.

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	P-2507-AU3	 	Australia	 	2005305456	 	17-Nov-2005	 	17-Nov-2004	 	Patented	 	YEDGAR, Saul	 	Use of MFAIDs to treat asthma, allergic rhinitis, or COPD.
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	P-2507-EA3	 	Eurasia	 	200701077

        Patent No. 012138
	 	17-Nov-2005	 	17-Nov-2004	 	Patented	 	YEDGAR, Saul	 	Use of MFAIDs to treat asthma, allergic rhinitis, or COPD.
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	P-2507-CN3	 	China	 	200580046771.3

        Patent No. ZL200580046771.3
	 	17-Nov-2005	 	17-Nov-2004	 	Patented	 	YEDGAR, Saul	 	Use of phospholipid-ethanolamine-glycosaminoglycan conjugates to treat asthma, COPD or allergic
    rhinitis.

 

    	- 26 -

    	 

    

 

Rest of the World Pending Patent Applications

 

	PCZL Ref.

    No.	 	Country	 	Application #	 	Filing Date	 	Priority

    Date	 	Status	 	Inventor/s	 	Claimed
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	P-2507-EP	 	Europe	 	01900237.7	 	10-Jan-2001	 	10-Jan-2000	 	Pending	 	YEDGAR, Saul; SHOSEYOV, David; GOLOMB, Gershon; REICH, Reuven; GINSBURG, Isaac; HIGAZI, Abd-al-Roof;
    LIGUMSKI, Moshe; KRIMSKY, Miron; OJCIUS, David; YARD, Benito Antonio; van der WOUDE, Fokko Johannes; SCHNITZER, Edit	 	1. MFAID compounds.

        2. The Use of MFAIDs to
        treat a variety of diseases.

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	P-2507-JP4	 	Japan	 	2011-105921	 	11-May-2011	 	10-Jan-2001	 	Pending	 	YEDGAR, Saul; SHOSEYOV, David; GOLOMB, Gershon; REICH, Reuven; GINSBURG, Isaac; HIGAZI, Abd-al-Roof;
    LIGUMSKI, Moshe; KRIMSKY, Miron; OJCIUS, David; YARD, Benito Antonio; van der WOUDE, Fokko Johannes; SCHNITZER, Edit	 	Divisional of 2507-JP

        1. MFAID compounds.

        2. The Use of MFAIDs to
        treat a variety of diseases and disorders.

 

    	- 27 -

    	 

    

 

	PCZL Ref.

    No.	 	Country	 	Application #	 	Filing Date	 	Priority

    Date	 	Status	 	Inventor/s	 	Claimed
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	P-2507-AU4	 	Australia	 	2011201154	 	15-Mar-2011	 	2-Mar-2005	 	Pending	 	YEDGAR, Saul	 	Divisional of 2507-AU2

        1. MFAID compounds.

        2. Use of MFAID compounds
        to a variety of diseases and disorders.

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	P-2507-AU5	 	Australia	 	2011213739	 	18-Aug-2011	 	17-Nov-2004	 	Pending	 	YEDGAR, Saul	 	Divisional of 2507-AU3

        Use of MFAIDs to treat
        asthma, allergic rhinitis, or COPD.

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	P-2507-CA2	 	Canada	 	2558416	 	02-Mar-2005	 	2-Mar-2004	 	Pending	 	YEDGAR, Saul	 	1. MFAID compounds.

        2. The Use of MFAIDs to
        treat a variety of diseases and disorders.

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	P-2507-EP2	 	Europe	 	05724186.1	 	02-Mar-2005	 	2-Mar-2004	 	Pending	 	YEDGAR, Saul	 	1. MFAID compounds.

        2. The Use of MFAIDs to
        treat a variety of diseases and disorders.

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	P-2507-HK	 	Hong Kong	 	07109751.3	 	07-Sep-2007	 	2-Mar-2004	 	Pending	 	YEDGAR, Saul	 	Same as P-2507-EP2
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	P-2507-JP2	 	Japan	 	2007-501901	 	02-Mar-2005	 	2-Mar-2005	 	Pending	 	YEDGAR, Saul	 	1. MFAID compounds.

        2. The Use of MFAIDs to
        treat a variety of diseases and disorders.

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	P-2507-CA3	 	Canada	 	2587883	 	17-Nov-2005	 	17-Nov-2004	 	Pending	 	YEDGAR, Saul	 	Use of MFAIDs to treat asthma, allergic rhinitis, or COPD.

 

    	- 28 -

    	 

    

 

	PCZL Ref.

    No.	 	Country	 	Application #	 	Filing Date	 	Priority

    Date	 	Status	 	Inventor/s	 	Claimed
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	P-2507-EP3	 	Europe	 	05808267.8	 	17-Nov-2005	 	17-Nov-2004	 	Pending	 	YEDGAR, Saul	 	Compounds for use of MFAIDs to treat or prevent asthma, allergic rhinitis, or COPD.
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	P-2507-IL3	 	Israel	 	183227	 	17-Nov-2005	 	17-Nov-2004	 	Pending	 	YEDGAR, Saul	 	Use of phosphotidylethanolamine glycosaminoglycan conjugates to treat or reduce the symptoms
    of asthma or COPD.
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	P-2507-IL5	 	Israel	 	212214	 	07-Apr-2011	 	17-Nov-2004	 	Pending	 	YEDGAR, Saul	 	Divisional of P-2507-IL3

        Use of MFAIDs to treat
        or prevent allergic rhinitis.

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	P-2507-IL6	 	Israel	 	212215	 	07-Apr-2011	 	17-Nov-2004	 	Pending	 	YEDGAR, Saul	 	Divisional of P-2507-IL3

        Use of MFAIDs to treat
        or prevent COPD.

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	P-2507-JP3	 	Japan	 	2007-542507	 	17-Nov-2005	 	17-Nov-2004	 	Pending	 	YEDGAR, Saul	 	Use of MFAIDs to treat asthma or allergic rhinitis.
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	P-2507-JP5	 	Japan	 	2011-199088	 	13-Sep-2011	 	2-Mar-2004	 	Pending	 	YEDGAR, Saul	 	Divisional of P-2507-JP3

        Use of MFAIDs to treat
        asthma, allergic rhinitis, or COPD.

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	P-2507-JP6	 	Japan	 	2011-255723	 	24-Nov-2011	 	17-Nov-2004	 	Pending	 	YEDGAR, Saul	 	Divisional of P-2507-JP2

        1. MFAID compounds.

        2. The Use of MFAIDs to
        treat a variety of diseases and disorders.

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	P-2507-MX3	 	Mexico	 	MX/a/2007/005975	 	17-Nov-2005	 	17-Nov-2004	 	Allowed	 	YEDGAR, Saul	 	Use of MFAIDs to treat asthma, allergic rhinitis, or COPD.
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	P-8131-AU	 	Australia	 	2006278657	 	01-Aug-2006	 	03-Aug-2005	 	Pending	 	YEDGAR, Saul; PRINCE, Alice	 	Use of MFAIDs to treat cystic fibrosis.

 

    	- 29 -

    	 

    

 

	PCZL Ref.

    No.	 	Country	 	Application #	 	Filing Date	 	Priority

    Date	 	Status	 	Inventor/s	 	Claimed
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	P-8131-CA	 	Canada	 	2617484	 	01-Aug-2006	 	03-Aug-2005	 	Pending	 	PRINCE, Alice; YEDGAR, Saul	 	Use of MFAIDs to treat cystic fibrosis.
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	P-8131-CN	 	China	 	20068000037016.3	 	01-Aug-2006	 	03-Aug-2005	 	Pending	 	YEDGAR, Saul; PRINCE, Alice; COHEN, Yuval	 	Use of MFAIDs to treat cystic fibrosis.
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	P-8131-EA	 	Eurasia	 	200800489	 	01-Aug-2006	 	03-Aug-2005	 	Pending	 	PRINCE, Alice; YEDGAR, Saul	 	Use of MFAIDs to treat cystic fibrosis.
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	P-8131-EP	 	Europe	 	EP06800600.6	 	01-Aug-2006	 	03-Aug-2005	 	Pending	 	PRINCE, Alice; YEDGAR, Saul; COHEN, Yuval	 	Use of MFAIDs to treat cystic fibrosis.
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	P-8131-IL	 	Israel	 	189171	 	01-Aug-2006	 	03-Aug-2005	 	Pending	 	PRINCE, Alice; YEDGAR, Saul	 	Use of MFAIDs to treat cystic fibrosis.
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	P-8131-JP	 	Japan	 	2008525110	 	01-Aug-2006	 	03-Aug-2005	 	Pending	 	PRINCE, Alice; YEDGAR, Saul	 	Use of MFAIDs to treat cystic fibrosis.
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	P-8131-KR	 	Korea	 	10-2008-7005229	 	01-Aug-2006	 	03-Aug-2005	 	Pending	 	YEDGAR, Saul; PRINCE, Alice	 	Use of MFAIDs to treat cystic fibrosis.
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	P-8131-MX	 	Mexico	 	MX/a2008/001639	 	01-Aug-2006	 	03-Aug-2005	 	Pending	 	PRINCE, Alice; YEDGAR, Saul	 	Use of MFAIDs to treat cystic fibrosis.
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	P-8653-AU	 	Australia	 	2007224324	 	11-Mar-2007	 	09-Mar-2006	 	Pending	 	YEDGAR, Saul	 	Catheters and stents coated with MFAIDs.
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	P-8653-CA	 	Canada	 	2645079	 	11-Mar-2007	 	09-Mar-2006	 	Pending	 	YEDGAR, Saul	 	Catheters and stents coated with MFAIDs.
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	P-8653-CN	 	China	 	200780016485.1	 	11-Mar-2007	 	09-Mar-2006	 	Pending	 	YEDGAR, Saul	 	Catheters and stents coated with MFAIDs.

 

    	- 30 -

    	 

    

 

	PCZL Ref.

    No.	 	Country	 	Application #	 	Filing Date	 	Priority

    Date	 	Status	 	Inventor/s	 	Claimed
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	P-8653-IL	 	Israel	 	193979	 	11-Mar-2007	 	09-Mar-2006	 	Pending	 	YEDGAR, Saul	 	Catheters and stents coated with MFAIDs.
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	P-8967-AU	 	Australia	 	2007320737	 	14-Nov-2007	 	14-Nov-2006	 	Pending	 	YEDGAR, Saul; COHEN, Yuval	 	A contact lens comprising MFAIDs.
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	P-8967-EP	 	Europe	 	07827381.0	 	14-Nov-2007	 	14-Nov-2006	 	Pending	 	YEDGAR, Saul; COHEN, Yuval	 	A contact lens comprising MFAIDs.
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	P-8967-AU1	 	Australia	 	2007320736	 	14-Nov-2007	 	14-Nov-2006	 	Pending	 	YEDGAR, Saul; COHEN, Yuval	 	1. Use of MFAIDs to treat
        eye disorders.

        2. Contact lens solutions
        comprising MFAIDs.

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	P-8967-CA1	 	Canada	 	2705785	 	14-Nov-2007	 	14-Nov-2006	 	Pending	 	YEDGAR, Saul; COHEN, Yuval	 	1. Use of MFAIDs to treat
        eye disorders.

        2. Contact lens solutions
        comprising MFAIDs.

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	P-8967-CN1	 	China	 	200780049831.6	 	14-Nov-2007	 	14-Nov-2006	 	Pending	 	YEDGAR, Saul; COHEN, Yuval	 	1. Use of MFAIDs to treat
        eye disorders.

        2. Contact lens solutions
        comprising MFAIDs.

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	P-8967-EP1	 	Europe	 	07827380.2	 	14-Nov-2007	 	14-Nov-2006	 	Pending	 	YEDGAR, Saul; COHEN, Yuval	 	1. Use of MFAIDs to treat
        eye disorders.

        2. Contact lens solutions
        comprising MFAIDs.

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	P-71126-AU	 	Australia	 	Not yet known	 	11-May-2010	 	11-May-2009	 	Pending	 	YEDGAR, Saul; COHEN, Yuval; BONDI, Joseph V.	 	Low molecular weight phospholipid-glycosaminoglycan conjugate compositions.
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	P-71126-CA	 	Canada	 	2,761,590	 	11-May-2010	 	11-May-2009	 	Pending	 	YEDGAR, Saul; COHEN, Yuval; BONDI, Joseph V.	 	Low molecular weight phospholipid-glycosaminoglycan conjugate compositions.

 

    	- 31 -

    	 

    

 

	PCZL Ref.

    No.	 	Country	 	Application #	 	Filing Date	 	Priority

    Date	 	Status	 	Inventor/s	 	Claimed
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	P-71126-CN	 	China	 	Not yet known	 	11-May-2010	 	11-May-2009	 	Pending	 	YEDGAR, Saul; COHEN, Yuval; BONDI, Joseph V.	 	Low molecular weight phospholipid-glycosaminoglycan conjugate compositions.
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	P-71126-EP	 	Europe	 	10775366.7	 	11-May-2010	 	11-May-2009	 	Pending	 	YEDGAR, Saul; COHEN, Yuval; BONDI, Joseph V.	 	Low molecular weight phospholipid-glycosaminoglycan conjugate compositions.
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	P-71126-IL	 	Israel	 	216203	 	11-May-2010	 	11-May-2009	 	Pending	 	YEDGAR, Saul; COHEN, Yuval; BONDI, Joseph V.	 	Low molecular weight phospholipid-glycosaminoglycan conjugate compositions.
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	P-71126-JP	 	Japan	 	Not yet known	 	11-May-2010	 	11-May-2009	 	Pending	 	YEDGAR, Saul; COHEN, Yuval; BONDI, Joseph V.	 	Low molecular weight phospholipid-glycosaminoglycan conjugate compositions.
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	P-73006-AU	 	Australia	 	2010247105	 	11-May-2010	 	11-May-2009	 	Pending	 	YEDGAR, Saul	 	Methods of treating cancers and disorders associated with matrix metalloproteinases using
    phosphatidylethanolamine glycosaminoglycan conjugates or phosphatidylserine glycosaminoglycan conjugates.
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	P-73006-CA	 	Canada	 	2,761,605	 	11-May-2010	 	11-May-2009	 	Pending	 	YEDGAR, Saul	 	Methods of treating cancers and disorders associated with matrix metalloproteinases using
    phosphatidylethanolamine glycosaminoglycan conjugates or phosphatidylserine glycosaminoglycan conjugates.

 

    	- 32 -

    	 

    

 

	PCZL Ref.

    No.	 	Country	 	Application #	 	Filing Date	 	Priority

    Date	 	Status	 	Inventor/s	 	Claimed
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	P-73006-CN	 	China	 	Not yet known	 	11-May-2010	 	11-May-2009	 	Pending	 	YEDGAR, Saul	 	Methods of treating cancers and disorders associated with matrix metalloproteinases using
    phosphatidylethanolamine glycosaminoglycan conjugates or phosphatidylserine glycosaminoglycan conjugates.
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	P-73006-EP	 	Europe	 	10774611.7	 	11-May-2010	 	11-May-2009	 	Pending	 	YEDGAR, Saul	 	Methods of treating cancers and disorders associated with matrix metalloproteinases using
    phosphatidylethanolamine glycosaminoglycan conjugates or phosphatidylserine glycosaminoglycan conjugates.
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	P-73006-IL	 	Israel	 	216205	 	11-May-2010	 	11-May-2009	 	Pending	 	YEDGAR, Saul	 	Methods of treating cancers and disorders associated with matrix metalloproteinases using
    phosphatidylethanolamine glycosaminoglycan conjugates or phosphatidylserine glycosaminoglycan conjugates.
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	P-73006-JP	 	Japan	 	Not yet known	 	11-May-2010	 	11-May-2009	 	Pending	 	YEDGAR, Saul	 	Methods of treating cancers and disorders associated with matrix metalloproteinases using
    phosphatidylethanolamine glycosaminoglycan conjugates or phosphatidylserine glycosaminoglycan conjugates.

 

    	- 33 -Yissum Research
Development Company

of the Hebrew University of Jerusalem HI

 Tech Park, Edmond J. Safra
Campus

Givat Ram, PO Box 3S13S Jerusalem

91390, Israel

 

Re:
Agreement for the Rendering of Services Between Morria and Yissum

 

		1.	Morria Biopharmaceuticals, 53 Davies Street
Mayfair London W1K5JH, (hereinafter "the Company") hereby requests that the following laboratory services as set forth
in Appendix A attached hereto performed via Yissum. As detailed in the addendum to this document which constitutes an inseparable
part of the Agreement (hereinafter "Services"). 

 

		2.	The Services are to be performed in accordance
with, the time schedule enclosed with this letter, which shall be understood as an integral part of this document

 

		3.	The Services will be performed by or under
the control and supervision of Dr. Saul Yedgar (hereinafter "the Researcher"). Yissum and Researcher agree to provide
such Services. Researcher shall not and will not co-mingle any funds, data, information, results and/or materials, resulting from
a grant from another party, entity or person with the funds, data, information, results and/or materials resulting from the grant
of Morria provided in Paragraph 5 below.

 

		4.	The scientific report and all reports,
information, data, materials, and methods that will be generated as a result of the Services rendered will be presented directly
to the Company at the earliest possible date by Dr. Yedgar

 

		5.	In consideration for provision of the
Services, the Company shall be obligated to pay the total sum of up to USD 90,000, to Yissum, which shall be paid on the following
dates; .

i.USD
40,000. - within one month of signing this contract

ii.USD
30,000. - by November 1st, 2005

iii.USD
20,000 - 20,000.׳ an February 1st, 2006

So
as to remove all doubt, the Company hereby states that Yissum is not expected to present any financial report and that the expenses
incurred in rendering the Services shall be Yissum's responsibility alone.

 

		6.	Any compositions, data, intellectual property,
inventions, information, improvements, know-how, materials, methods, patents, patent applications, processes, results, and/or technology
that are conceived and/or developed, result from, or arise under the Services ("Service Agreement Results") shall be
owned by Yissum, Yissum hereby grants the Company a worldwide exclusive, license and right, to the Service Agreement Results, with
the right to sublicense, under the same terms and conditions as set forth, in the Exclusive License Agreement between the parties
dated the 27lh day of November 2002 (the "Exclusive License Agreement"), and to make, have made, use, have
used, sell, have sold, import, license, and distribute any product resulting from the Service Agreement Results covered by a Valid
Claim (as defined in the License Agreement). 

 

    	 

    	 

    

 

		7.	All terms and conditions of the Exclusive
License Agreement shall apply to this Agreement, and the exclusive license of the Service Agreement Results in Paragraph 6.

		8.	So as to remove all doubt, the Company
hereby states that Yissum's and/or the Company's relationship with the Researchers shall not be that of employer-employee, but
that of requester-independent contractor.

		9.	In all cases in which a dispute shall
arise between the Company and Yissum regarding the Services, a single arbitrator shall be chosen with the agreement of both sides
and shall be called upon to decide, and if such an agreement is not achieved, an arbitrator shall be appointed at the request of
either party by the President of the Bar Association, Jerusalem branch.

		10.	The Company shall not make any use of
any kind of the name of the Researcher(s) or Yissum or the Hebrew University without the prior written consent of Yissum, which
shall not be unreasonably withheld.

		11.	Signature by an authorized representative
of Yissum on this copy of the document shall constitute Yissum's approval and agreement to all that is written herein.

 

Yissum
hereby agrees and approves:

 

	Name: /s/ AVI
    BARAK /s/REUVEN RON	Date: June 20, 2005
	 Title:	 
	Yissum Research Development Company	 
	of the Hebrew University of Jerusalem	 
	 	 
	Morria Biopharmaceuticals, Plc.	 
	/s/ YUVAL COHEN	 
	Yuval Cohen	June 9th 2005
	Managing Director	 

 

Researcher's
Agreement:

I
the undersigned, Prof. Saul Yedgar, of the Hebrew University, have reviewed, am familiar with and agree to all of the above terms
and conditions, thereby undertake to fully cooperate with Yissum in order to ensure its ability to fulfill its obligations hereunder,
as set forth herein.

 

	/s/ Saul Yedgar	 
	Date signed; June 9, 2005

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00205-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00205-of-00352.parquet"}]]